Corrected: BenchSci raises $70M Series D for drug discovery software; Zentalis touts PhIb ovarian cancer data
Canada’s BenchSci has raised $70 million in a Series D round designed to scale its AI drug discovery platform for scientists working in preclinical research.
The company boasts thousands of clients for its software, including 16 of the top 20 pharmaceutical companies. On the platform, researchers can get a digest of AI’s summary of medical, clinical and research data — helping them spot biological connections and choose among thousands of options with, say, a reagent or antibody.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.